The Motley Fool··Jonathan PoncianoMajor Investor Trims $104M Nuvalent Stake as Cancer Drug Developer Surges 30%
Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.
ABBVNUVLTERNBMRNFDA approvalbiotech